Work

Safety of resuming anti-PD-1 (aPD1) in patients (pts) with immune-related adverse events (irAEs) during combined anti-CTLA-4 (aCTLA4) and aPD1 in metastatic melanoma (MM).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.9544

Authors: Megan Pollack, Allison Shayna Betof, Katherine Rappazzo, Ian Valentine, Zeynep Eroglu, Douglas Buckner Johnson, Alexander Noor Shoushtari

Institutions: Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891493279

Cites:

Cited by: 1

Related to: 10